Compare Moderna, Inc. (MRNA) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sibanye Stillwater Ltd — how do they compare? Moderna, Inc. trades at $219.97 (market cap $78.65B), while Sibanye Stillwater Ltd trades at $9.99 (market cap $6.88B). The key difference: Moderna, Inc. is far larger — about 11.4× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Sibanye Stillwater Ltd for 51 Days on average.
| MRNA | SBSW | |
|---|---|---|
Market Cap | $78.65B | $6.88B |
Volume | 37,373,437 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $203.46 | $21.12 |
52-Week Low | $22.36 | $8.00 |
Typical Hold Time | 59 Days | 51 Days |
Enterprise Value | $74.80B | $7.78B |
Dividend Yield | — | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
SBSW trades at $9.99, up 3.2% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong operational improvement with 2025 revenue reaching $129.68B and positive net cash flow of $1.13B, though it posted a net loss of $5.17B. Recent Q2 2026 earnings beat expectations with $1.34 EPS versus $1.26 expected, indicating potential turnaround momentum. Analyst consensus remains positive with a $14.25 price target representing 43% upside potential from current levels.
The stock presents a compelling value opportunity with attractive valuation multiples (P/E 8.12, P/S 0.7) and strong profitability metrics (ROE 34.37%), but faces execution risks from recent net losses and high debt levels. Key catalysts include continued operational improvements and commodity price support, while risks involve debt management and margin pressures. Institutional sentiment appears constructive with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
